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Nowadays, mesenchymal stem cells (MSCs) are essential 
players in cellular therapy and regenerative medicine. 
MSCs are used to treat cardiac disorders by intramyo-
cardial injection or injection into the bloodstream. 
Therefore, a premise of successful MSC-based therapy 
is that the cells reach the site of injury and home the 
damaged tissue. In response to inflammatory condi-
tions, MSCs can potentially move into the place of in-
jury and colonize damaged tissues, where they partici-
pate in their regeneration. This review presents the cur-
rent knowledge of the mechanisms of MSCs migration 
and target tissue homing in the field of cardiovascular 
therapies.
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INTRODUCTION
Mesenchymal stem cells (MSCs) represent a popu-
lation of undifferentiated cells, multipotent, with the 
ability to self-renew and differentiate into many cell 
types. They carry markers similar to those of tissue 
fibroblasts and are difficult to distinguish from them. 
For the first time, Friedenstein and others (Frieden-
stein et al., 1970) described bone marrow-derived fi-
broblast-like cells which later became the most ex-
tensively studied MSCs. Subsequently these cells were 
also found in the adipose tissue, muscle, dental pulp, 
periosteum, synovium, and synovial fluid, tendons, 
endometrium, skin, lungs, chorionic villi, peripher-
al blood, menstrual blood, breast milk, as well as in 
umbilical cord, Wharton’s jelly, placenta, and umbili-
cal cord blood (Eleuteri & Fierabracci, 2019; Berebi-
chez-Fridman & Montero-Olvera, 2018; Kong et al., 
2019).
The minimum criteria to be fulfilled by a cell to be 
classified as a mesenchymal stem cell were stated in a 
paper published by the International Society for Cellu-
lar Therapy (ISCT) in 2006 (Dominici et al., 2006). As 
per this statement, cells need to satisfy three condi-
tions to be recognized as MSC (Table 1). Even though 
a wide range of selection markers defining MSCs were 
identified, no single marker specific only to them has 
been indicated.
In response to inflammatory conditions, MSCs can 
potentially move into the site of injury and colonize 
the damaged tissues, where they participate in their 
regeneration (Murphy et al., 2013; Rosenthal, 2003). 
The efficacy of MSC-based therapy depends on their 
homing ability and engraftment into the target tissue. 
The possibility of using MSCs in the therapy of many 
diseases needs to be preceded, though, by an in-depth 
analysis of their properties, especially by determin-
ing the mechanism of tissue homing, as well as the 
mechanism due to which the cells contribute to tissue 
regeneration.
This review presents the current knowledge of the 
mechanisms of MSCs migration, homing, and cardiac 
tissue regeneration, hoping to develop an effective 
treatment for cardiovascular diseases and many other 
clinical applications.
Table 1. General characteristics of mesenchymal stem cells.
Morphology Spindle-shaped, fibroblast-like
Growth properties adherent
Surface markers CD73+, CD90+, CD105+, CD11b-, CD14-, CD19-, CD45-, CD79α-, HLA-DR-, MHC-II-
In vitro differentiation potential osteogenic, chondrogenic, adipogenic
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WHY MSCs?
MSCs can be of great significance for healing tissue 
damage owing to their distribution in a wide range of 
tissues, their differentiation potential, and the reparative 
effects noticed when MSCs are infused in pre-clinical 
and clinical models (Wei et al., 2013). It is widely accept-
ed that there are roles for MSCs in tissue growth, wound 
healing, and maintenance of the cell supply to compen-
sate for the cells’ lost due to apoptosis and pathology. 
Due to these roles, researchers and clinicians have used 
MSCs for treating tissue damage.
Numerous studies were performed, indicating the ef-
fectiveness of MSCs’ application to decrease the postin-
farction myocardial scarring and restore regular systolic 
function in case of acute myocardial infarction (Afzal 
et al., 2015; Majka et al., 2017). MSCs exhibit high che-
motaxis into damaged tissues, and areas embodied with 
inflammatory reaction and oxygen deficiency, thus con-
ditions dominating in ischemic damaged tissue of car-
diac muscle (Sohni & Verfaillie, 2013). However, the 
exact mechanism due to which the cells contribute to 
regeneration of the cardiac muscle is still unknown. 
Supposedly, this process depends on many factors and 
probably does rely on a direct ability of MSCs to di-
versify towards cardiomyocytes, but on their ability to 
release cytokines and growth factors with trophic prop-
erties (Gnecchi & Cervio, 2013; Yamahara & Nagaya, 
2007). Among fundamental mechanisms of mesenchy-
mal stem cells action, the most important is secretion 
of the paracrine factors and integration at the cellular 
level (Markel et al., 2008; Mirotsou et al., 2007; Karan-
talis & Hare, 2015). MSCs can also contribute to atten-
uation of inflammatory conditions and stimulation of 
endogenous repair mechanisms through their immuno-
suppressive properties (Hamid & Prabhu, 2017; Kocher 
et al., 2001; Ward et al., 2018).
MSCs secrete TNF-α, IL-6, and IL-8 cytokines sug-
gested as potential mediators of heart preservation 
(Hatzistergos et al., 2010; Molina et al., 2009). It was 
demonstrated that proinflammatory cytokines increase 
immunity of cardiomyocytes to ischemia (Molina et al., 
2009). Additionally, IL-8 is known to influence cell pro-
liferation and angiogenesis. MSCs also secrete growth 
factors, including granulocyte and macrophage colo-
ny-stimulating factors, as well as the FMS-like tyrosine 
kinase 3 (Hodgkinson et al., 2016). Growth factors are 
capable of inducing myocardium by restraining apop-
tosis of cardiomyocytes in the implantation area, and 
further secreting antiapoptotic and angiogenic factors, 
such as the vascular endothelial growth factor (VEGF) 
that stimulates angiogenesis (Markel et al., 2008) and 
sFRP2 protein that modulates the Wnt signaling path-
way (Mirotsou et al., 2007). Secretion of angiogenic 
factors is crucial for neovascularization of the cardiac 
muscle after heart attack, as mesenchymal stem cells 
lacking VEGF are less efficient at myocardial regenera-
tion after injury (Markel et al., 2008).
In addition to cytokines, mesenchymal stem cells also 
secrete metalloproteinases which reorganize the extra-
cellular matrix (ECM) in the scar tissue (Molina et al., 
2009). Reversed remodeling of the scar tissue and anti-
fibrotic effects in the necrotic tissue of the heart mus-
cle are essential for regeneration and functional resto-
ration of the heart after myocardial infarction. Further, 
mesenchymal stem cells stimulate the proliferation and 
differentiation of endogenous cardiac stem cells, simul-
taneously contributing to the cardiac muscle regeneration 
(Hatzistergos et al., 2010).
Moreover, MSCs also immediately interact with other 
cell types through interactions at the cellular level. Ow-
ing to direct and intermediate cell communication and 
signaling with cells in the damaged areas, MSCs recruit 
other stem cells to facilitate regeneration of the damaged 
tissue. An excellent example of the mentioned type of 
interactions is the signaling pathway SDF-1α/CXCR4 
that regulates cell migration of hematopoietic stem cells 
to the damaged myocardium (Elmadbouh et al., 2007; 
Zhang et al., 2007).
MSCs can also serve as an exosome provider (Lai et 
al., 2015). Exosomes play an essential role in cellular 
communication and change biochemical characteristics 
of the recipient cells by providing biomolecules (Wang 
et al., 2018). These bubbles are produced from body 
fluids and various cell types, such as MSCs (Zeringer et 
al., 2015). Evidence suggests that the mesenchymal stem 
cells-derived exosome (MSC-EXO) has MSC-like func-
tions with low immunogenicity and no carcinogenic po-
tential. Studies performed by Zhao et al. in a rat model 
of acute myocardial infarction have shown that the use 
of HUC-MSC-EXO and micro-vesicles can improve car-
diac function after four weeks of HUC-MSC-EXO in-
jection (Zhao et al., 2015). Also, reduced cardiac fibrosis 
was observed after Masson’s trichrome staining. 
RECRUITMENT AND HOMING OF MSCs
Molecular factors involved in MSCs migration
A premise of successful MSC-based therapy is that 
the cells reach the site of injury and home the damaged 
tissue, which is possible due to their ability to reach the 
damaged places thanks to their ability to migrate, adhere, 
and get implanted into the target tissue. Therapeutic effi-
cacy and target tissue homing by MSCs are influenced by 
several factors, such as the source of the cells, the age 
of the donor, breeding conditions, the number of pas-
sages,  method of supplying cells, the number of cells 
implanted, general condition and susceptibility of the 
host (Beane et al., 2014; Siegel et al., 2013; Izadpanah et 
al., 2008; Zhuang et al., 2015). It has been proven that 
freshly isolated cells have higher engraftment in tissue 
and more efficient target tissue homing when compared 
to cells from long-term in vitro expansion (Rombouts & 
Ploemacher, 2003; Hong et al., 2019). This probably re-
sults from aging and differentiation of MSCs during in 
vitro cultivation (Trounson & McDonald, 2015). Culture 
conditions also have a significant impact on the MSCs 
homing, as they can modify expression of the surface 
markers involved in this process (Yang et al., 2018).
The site and method used for administration of MSCs 
for therapeutic purposes can influence the way taken by 
cells to reach the desired destination (Boltze et al., 2015). 
Usually, MSCs are administrated systemically by injection 
into the bloodstream. Therefore, the necessary condition 
for an effective therapy based on MSCs is the capacity 
of the used cells to get to the site of injury and to oc-
cupy tissue affected by the disease. The remedial effect 
is most likely a result of increased migration of cells to-
wards the damaged tissue, preceded by MSCs adhesion 
to vascular endothelial cells. 
Many studies have shown that MSCs are capable of 
directional migration in response to inflammatory con-
ditions (Nakajima et al., 2012; Zachar et al., 2016; Yagi 
et al., 2010). MSCs are thought to use the same mecha-
nism of migration into a tissue as leukocytes (Nitzsche 
et al., 2017). However, in contrast to the well-described 
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mechanisms of leukocyte adhesion and movement, the 
mechanism of tissue homing by MSCs is not yet fully 
understood, despite the fact that there are numerous 
studies assessing MSCs adhesive molecules and possible 
mechanisms of vascular wall adhesion and migration, 
as well as evaluating the role of chemokines in guiding 
MSCs to the target tissues (Kia et al., 2011; Ghaffari-
Nazari, 2018). 
Before MSCs migrate through the wall of a vessel, 
they are rolling on its surface, finding the best place 
for adhesion and then transmigrating through the en-
dothelium (Fig. 1) (Nitzsche et al., 2017). The interac-
tion of integrins that are expressed in the MSCs’ cell 
membrane with adhesion molecules at the endothelial 
surface (VCAM and ICAM) can lead to formation of 
docking structures and transmigration wells that are rich 
in ICAM-1, VCAM-1, proteins, and cytoskeleton com-
ponents (Nitzsche et al., 2017; De Becker & Van Riet, 
2016).
To date, several molecules involved in interactions be-
tween MSCs and endothelial cells were indicated, includ-
ing VLA-4, VCAM-1, ICAM-1, and P-selectin. Adhesion 
molecules, such as selectins, integrins, and chemokine 
receptors, are committed to rolling, adhesion, and trans-
migration of MSCs. Mesenchymal stem cells have been 
shown to express various receptors associated with in-
tercellular contacts and adherence to extracellular matrix 
proteins, such as α1, α2, α3, α4, α5, αv, β1, β3 and β4 
integrins, and other adhesion molecules, i.e. VCAM-1, 
ICAM-1, ICAM-3, CD166 (ALCAM) (Rüster et al., 2006; 
Ip et al., 2007). Some studies have shown that MSCs 
adhesion to the endothelium occurs with participation 
of P-selectin. It has been observed that MSCs may use 
new carbohydrate ligands to interact with P-selectin on 
the endothelial surface (Rüster et al., 2006). Steingen et 
al. reported that MSCs could migrate through endothe-
lium using the VLA-4/VCAM-1 complex, and that 
MSCs tend to integrate with the endothelial layer instead 
of passing full diapedesis (Steingen et al., 2008). Among 
the integrin family, a key role in adhesion, migration, and 
chemotaxis is played by integrin α4β1, which is a media-
tor in the cell-cell contact and cell-environment interac-
tions. However, because the MSCs’ transendothelial mi-
gration has not been entirely blocked by the anti-VLA4 
antibody and the anti-VCAM-1 antibody, it can be as-
sumed that other integrins are also involved in this pro-
cess (Steingen et al., 2008).
Although integrins and selectins play an essential role 
in transmigration of MSCs, chemokines released from 
the tissues and endothelial cells can promote activation 
of ligands involved in adhesion, migration, chemotaxis 
and homing of MSCs in the target tissues. Many reports 
suggest that the damaged tissue releases specific factors 
that act as chemoattractants to facilitate adhesion, move-
ment, and homing of MSCs in the affected areas (Na-
kajima et al., 2012; Zachar et al., 2016; Yagi et al., 2010). 
Studies have shown that MSCs are capable of migrating 
to the inflamed tissues in response to factors that are 
regulated under inflammatory conditions. So far, many 
chemokines and growth factors have been identified that 
are involved in the migration process. These are proin-
flammatory cytokines, such as TNF-α, IL-1β, IL-6, IL-8, 
and many growth factors, e.g., EGF, FGF, HGF, IGF-1, 
PDGF-AB, SDF-1α, TGF-B1, VEGF-A (Fox et al., 2007; 
Honczarenko et al., 2005; Kortesidis et al., 2005; Lei-
bacher & Henschler, 2016; Guo et al., 2018). Some stud-
ies have shown expression of chemokine receptors by 
MSCs, including CXCR1–CXCR6, CCR1–CCR10, and 
have pointed to functional roles of some of them in the 
MSCs migration process (Honczarenko et al., 2005; Ringe 
et al., 2007; Lüttichau et al., 2005; Sordi et al., 2005). It 
has been proven that CXCR1, CXCR2, CXCR4, CCR1, 
CCR2, IL-8, MIP-1α, and MCP-1 are involved in migra-
tion of MSCs into the damaged tissue (Eseonu & De 
Bari, 2015).  Other studies have shown that the SDF-1/
CXCR4 axis plays a vital role in the movement of MSCs 
isolated from the bone marrow (Su et al., 2017; Kitaori et 
al., 2009). Therefore, it is likely that chemokines released 
from tissues cause expression of the CXCR4 receptor, 
which contributes to migration of MSCs to their final 
destination. It has been also shown that an increase in 
IL-8 concentration in the damaged tissues can activate 
the MSCs migration (Ringe et al., 2007). An active role of 
IL-6, PDGF, PDGFR-α PDGFR-β, vascular endothelial 
growth factor receptor 1 (FLT-1), and IGF-1 was indi-
cated in the BM-MSCs migration studies (Eseonu & De 
Bari, 2015). PDGFR has been highly expressed in the 
BM-MSCs, and PDGF induces BM-MSCs migration. A 
migration test through a porous filter also showed that 
PDGF has a stronger effect on MSCs chemotaxis than 
SDF-1 and MCP-1 (Lee et al., 2012). According to those 
studies, numerous chemokines play a role in induction 
of MSCs migration, but details, including mechanisms of 
colonization by MSCs, require further in vitro and in vivo 
studies.
An important role played by proteolytic enzymes – 
metalloproteinases which regulate the extracellular ma-
trix degradation, has been also confirmed (Steingen et al., 
2008; De Becker et al., 2007; Ries et al., 2007). Different 
MMPs and their signaling pathways have been shown 
to affect MSCs differentiation, migration, angiogenesis, 
and proliferation. Migration and invasion of MSCs into 
damaged tissues are facilitated by expression of CXCR4, 
MMP-2, and MT1-MMP (Almalki & Agrawal, 2016). In-
flammatory cytokines, such as IL-1β and TNF-α, stimu-
late production of MMPs by MSCs and activate chemot-
actic migration through the extracellular matrix (Sohni & 
Verfaillie, 2013).
Mechanical cues regulating MSCs movement
During migration through peripheral blood circulation 
towards the damaged tissue, exogenous MSCs inject-
ed into the body are exposed to various hemodynamic 
forces applied to the vessel walls, including shear stress 
and cyclic mechanical load. It has been observed that 
mechanical loads affect migration of MSCs. Studies by 
Zhang and others (Zhang et al., 2015) have shown that 
Figure 1. A potential mechanism of MCSs migration across the 
endothelium [source:  https://periobasics.com/mechanisms-of-
transendothelial-migration-of-leukocytes.html; modified; access 
on 19.09.2019].
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cyclic mechanical stretching (10%, 8 hours) promotes 
MSCs migration through the FAK-ERK1/2 pathway, 
but leads to a decrease in the invasive potential of MSCs 
by downregulating MT1 – MMP via the PI3K/Act sign-
aling pathway (Zhang et al., 2015; Fu et al., 2019).
Shear stress is another type of force inside the blood 
vessels. However, so far only a few studies have fo-
cused on the effects of shear stress on MSCs movement. 
It was observed that shear stress (~0.2 Pa) promoted 
MSCs migration in the wound healing test, while a high-
er shear stress (> 2 Pa) had significantly inhibited MSCs 
migration by regulating the JNK and p38 MAPK path-
ways (Yuan et al., 2012).
The ability of the cell to dynamically reshape is essen-
tial for migratory behavior due to physical limitations in 
the tissue (Rudzka et al., 2019; Xu et al., 2012). How a 
given cell remodels its shape is related to the cell de-
formability, and cell elasticity depends on the structure 
of the cytoskeleton (Olson & Sahai, 2009). Our recent 
studies have proven that the elasticity of MSCs observed 
by atomic force microscopy (AFM) is an important fac-
tor that determines the ability of MSCs to migrate across 
a porous filter (Szydlak et al., 2019). The results have 
shown that MSCs with the potential of transendothe-
lial migration and invasion were characterized by higher 
deformability (Szydlak et al., 2019). Previous studies per-
formed by McGrail et al. have demonstrated that loss 
of MSCs elasticity leads to a decrease in MSCs motil-
ity in the wound healing assay and transmigration tests 
(McGrail et al., 2013).
Furthermore, mechanical properties of the micro-
environment, such as the extracellular matrix elasticity, 
and mechanical and shear stresses occurring in the blood 
vessels, are crucial in MSCs migration. Biophysical sig-
nals that reach MSCs play an essential role in regulating 
their behavior.
Previous studies focused on the effect of extracellular 
matrix rigidity on MSCs migration. The research con-
ducted by Raab et al. showed that MSCs migrated from a 
soft substrate (1 kPa) towards the rigid surface (34 kPa) 
by cytoskeleton polarization and myosin-IIB heavy chain 
phosphorylation (myosin-IIB) (Raab et al., 2012), which 
suggests that mechanical properties of the substrate are 
regulating the MSCs polarization and migration. Other 
studies, conducted by Vincent et al., constructed sub-
strates with a stiffness gradient that was intended to sim-
ulate natural changes in the tissue stiffness, pathological 
changes, and tissues showing abrupt changes in stiffness. 
The results of this experiment showed that MSCs mi-
grated towards stiffer fragments, using the actin cytoskel-
eton for this purpose, and directional migration was car-
ried out using microtubules (Vincent et al., 2013).
The studies of the mechanism of MSCs’ migration are 
crucial for the development of MSC-based therapies be-
cause their ability to reach target tissue is a key factor 
in achieving therapeutic effectiveness. After recruitment 
and migration into the damaged tissues, MSCs will play 
their role and promote damaged tissue repair and organ 
regeneration, as well as reverse progression of the dis-
ease.
FUTURE DIRECTIONS
Despite promising results of clinical trials involving 
MSCs, there are ongoing efforts to increase the effec-
tiveness of MSCs, primarily because effects observed in 
the preclinical studies are stronger than in the clinical 
ones. Standardization of stem cell acquisition and culture 
methods is one of the fundamental challenges of mod-
ern cell therapy, and MSCs cell isolation and culture pro-
tocols to enhance safety of their in vivo use still require 
refinement. In addition, various methods are tested to 
increase the effectiveness of MSCs in vivo. They include a 
combination of MSCs therapy with standard pharmaco-
therapy (Ascheim et al., 2014), genetic engineering tech-
niques (Bobis-Wozowicz et al., 2011), biomaterials engi-
neering (Sekuła et al., 2017), MSCs pre-conditioning, e.g. 
by reducing oxygen availability (Ejtehadifar et al., 2015) 
or using an inflammatory factor (Hahn et al., 2008).
Although many studies (both preclinical and clinical) 
show more and more evidence of the therapeutic effec-
tiveness of MSCs, the main problem that remains is the 
low degree of retention of MSCs in the tissues due to 
their short-lived viability after implantation into the re-
cipient’s body (Von Bahr et al., 2012). The immune sta-
tus of the patient before and after injection determines 
survival of the implanted allogeneic MSCs. In vivo experi-
ments have shown that the time of MSCs transplantation 
decides on their therapeutic effect in a model of myocar-
dial infarction (Hu et al., 2007). Rigol et al. observed that 
MSCs induce better neovascularization and better long-
term prognosis when injected 15 minutes after reperfu-
sion than those injected a week later (Rigol et al., 2014). 
It has been detected that less than 10% of MSCs are 
retained in the damaged tissue 24 hours after injection 
into the body, and only about 1% is still at the site of 
injury after four weeks (Lee et al., 2011). In addition, it 
has been shown that after MSCs transplantation, many 
of them become trapped in the capillaries of the lungs, 
which reduces the population of cells occupying the tar-
get tissue (Rigol et al., 2014), and only a part of MSCs 
population responds to inflammatory factors and reaches 
the damaged tissue, e.g., in the case of infarcted myocar-
dium or ischemic damaged brain (Von Bahr et al., 2012; 
Barzegar et al., 2019). This problem was attempted to be 
solved by repeated MSCs injections. However, it was ob-
served that such a repeated administration might cause 
production of immune alloantibodies (Cho et al., 2008). 
Therefore, one of the biggest challenges faced by MSC-
based therapies is to improve engraftment efficiency.
An important factor is also the change in the expres-
sion of some adhesive molecules that occurs during 
long-term in vitro culture (Phinney & Prockop, 2007; De 
Becker et al., 2007). It has been observed that the in vitro 
expansion of MSCs gradually leads to a loss of expres-
sion of homing molecules and, in consequence, to a loss 
of tissue homing capacity by MSCs (Honczarenko et al., 
2005; Rombouts & Ploemacher, 2003).
The method of administration of MSCs can be an es-
sential factor in achieving the intended destination. Re-
searchers have tested many ways of providing MSCs that 
aim to ensure that these cells are successfully homed in 
the areas of ischemia, to prolong survival in the body in 
an inflammatory environment that will eventually lead to 
successful neovascularization. Also, non-invasive meth-
ods are considered due to the risks associated with op-
erational procedures. For example, in the treatment of 
brain damage, injecting MSCs directly into a damaged 
brain can bring high efficacy in therapy, but involves the 
risk of surgical complications that can be minimized by 
using less invasive or non-invasive techniques, or by sys-
temic administration. New methods of stem cell deliv-
ery are currently being tested. These include such tech-
niques as genetic modification of MSCs and cell surface 
engineering, in vitro pre-conditioning, and target tissue 
modification, as well as biomaterial engineering and cell 
scaffolding construction (Chen et al., 2018). In addition, 
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methods such as targeted administration, magnetic and 
ultrasound guidance, and radiotherapy techniques are 
being tested (Fakoya, 2017). The advantage of selective 
injection of these cells is reduced cell loss during cell de-
livery and migration, when compared to systemic admin-
istration (Kim et al., 2014).
On the other hand, the methods for labeling and de-
tection of MSCs in vivo after transplantation still need 
improvement.  Despite promising results of in vitro stud-
ies, there is lack of data about the behavior of MSCs 
after transplantation. That is why it is so important to 
be able to monitor the distribution, survival, and func-
tion of MSCs after in vivo transplantation, especially in 
patients. These needs have led to remarkable advances in 
molecular imaging, including magnetic resonance imag-
ing, scintigraphy, PET, optical imaging, and ultrasound, 
as well as multimodal imaging (Bose & Mattrey, 2019). 
Stem cell labeling with reporter genes or reporters to en-
able their detection and evaluation of their in vivo func-
tion was achieved using all current imaging methods 
with promising results in preclinical results and with 
some success in clinical trials as well (Wang & Jokerst, 
2016). However, currently there is no ideal approach to 
MSC imaging, each having advantages and limitations.
CONCLUDING REMARKS
The magical ability to regenerate damaged parts of the 
body to regain a lost function has been a dream of hu-
manity for a long time. MSC-based therapy is still an in-
novative and clinically needed therapeutic concept. The 
three properties of MSC make them optimal for tissue 
regeneration: (1) immunoregulatory ability is beneficial 
in alleviating abnormal immune responses, (2) parac-
rine or autocrine functions that generate growth factors, 
and (3) the ability to differentiate into target cells. De-
spite promising results of many studies, the biggest chal-
lenge of MSC-based therapies is to increase the target 
tissue retention. There is still need for basic research 
that will allow us to fully understand the in vivo mecha-
nisms of MSCs in the future. The proposed scheme of 
the relationship between MSC migration and tissue re-
pair is based on a chemotactic hypothesis. In response 
to inflammatory conditions, MSCs can potentially move 
into the site of injury and colonize the damaged tissues, 
where they participate in their regeneration. To date, 
many various factors have been recognized that affect 
MSCs migration, but the detailed mechanism involved in 
this proses is not yet fully understood. Answers to these 
questions would provide valuable information for further 
research and effective cellular therapy.
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